ArBlast Co., Ltd.
| Date |
Event |
| December 2005 |
Osteogenesis, Inc. and Amniotec Inc. merged to form a new company. Company name changed to ArBlast Co., Ltd. |
| June 2006 |
\252 million raised through allocation of new shares to third parties. |
| July 2006 |
Sale of cell processing system (CPS) started and CPS operation support services commenced. |
| July 2007 |
One of our activities was selected for subsidy project in 2007 by The New Energy and Industrial Technology Development Organization (NEDO) . |
| July 2007 |
\99.2 million raised through allocation of new shares to third parties. |
| September 2007 |
One of our activities was selected for subsidy project in 2007 by The New Energy and Industrial Technology Development Organization (NEDO) . |
| October 2007 |
\201.04 million raised through allocation of new shares to third parties. |
| May 2008 |
\130 million raised through allocation of new shares to third parties. |
| June 2008 |
The cultured corneal epithelial cell sheet designated as an Orphan Medical Device by MHLW (Ministry of Health, Labor and Welfare). |
| March 2009 |
\347million raised through allocation of new shares to third parties. |
| June 2009 |
The cultured corneal epithelial cell sheet was approved to enter clinical trials in Japan by MHLW following acceptance of the pre-clinical data package. |
| November 2009 |
\32 million raised through allocation of new shares to third parties. |
Osteogenesis, Inc.
| Date |
Event |
| December 2000 |
Osteogenesis established; offices located at 6-1 Minatojima-nakamachi, Chuo-ku, Kobe. |
| May 2001 |
Confirmed by Hyogo Prefecture as a New Growth Business (No. 96). |
| August 2001 |
Head office relocated to Kobe International Business Center at 5-5-2 Minatojima-minamimachi, Chuo-ku, Kobe. |
| September 2001 |
\50 million raised through allocation of new shares to third parties. |
| March 2002 |
Kansai Bureau of Economy, Trade and Industry (METI Kansai) selected “Research and Development on Injection-type Bone Formation Material Using Stem Cells” as a project to be granted a subsidy for R&D projects on technologies that contribute to the creation of new local industries. |
| July 2002 |
\75 million raised through allocation of new shares to third parties. |
| October 2002 |
Company’s own laboratory completed in Kobe International Business Center.
\225 million raised through allocation of new shares to third parties. |
| March 2003 |
Cell Processing Center (CPC) completed in Institute of Biomedical Research and Innovation. |
| March 2004 |
Concluded agreement with Espec Corp. concerning joint development of an automatic cell culture system. \72 million raised through allocation of new shares to Espec Corp. |
| May 2004 |
\336 million raised through allocation of new shares to third parties. |
| August 2004 |
The company’s “Business Innovation Plan” approved by Japan’s Small and Medium Enterprise Agency. |
| November 2004 |
\412.8 million raised through allocation of new shares to third parties. |
| February 2005 |
\5 million raised by using subscription warrants. |
| October 2005 |
\224.95 million raised through allocation of new shares to third parties. |
| December 2005 |
“Development of bone regeneration material using mesenchymal stem cells” selected by the National Institute of Biomedical Innovation as a project to which “Pharmaceuticals and Medical Devices Application Research Fund” program is applied. |
| December 2005 |
Merged with Amniotec Inc. |
Amniotec Inc.
| Date |
Event |
| August 2001 |
Amniotec Ltd. established in Machida City, Tokyo. |
| September 2001 |
Company reorganized into Amniotec Inc. (Capital: \10 million) |
| October 2001 |
Commenced joint R&D projects with Kyoto University and Kyoto Prefectural University of Medicine. |
| April 2002 |
Completed application for two basic patents relating to development of the oral mucosal cell sheet and the corneal endothelial cell sheet. |
| November 2002 |
\415 million raised through allocation of new shares to third parties. |
| December 2003 |
Company’s own laboratory completed in Kobe International Business Center.
Concluded agreement with Senju Pharmaceutical Co., Ltd. concerning joint clinical development in Japan of three amnion-based product lines for ophthalmologic use. |
| April 2004 |
Concluded agreement with Espec Corp. concerning joint development of an automatic culture system. |
| May 2004 |
\960 million raised through allocation of new shares to third parties. |
| November 2004 |
Executed five-for-one common stock split. |
| December 2004 |
\38.4 million raised through allocation of new shares to third parties. |
| January 2005 |
Company’s head office relocated to 1-chome, Kudan-kita, Chiyoda-ku, Tokyo. |
| June 2005 |
“Course on Corneal Tissue Regeneration Funded by Amniotec Co., Ltd.” opened at University of Tokyo. |
| December 2005 |
Merged with Osteogenesis, Inc. |
